Major Depressive Disorder Shares Immune Signature with Atopic Dermatitis, Opening New Treatment Avenues: Study Suggests
USA: Major Depressive Disorder (MDD), a debilitating psychiatric condition affecting millions worldwide, shares a distinct Type 2 helper T-cell (Th2) immune signature with atopic dermatitis (AD), a common inflammatory skin disease. This discovery highlights how preclinical inhibition of the interleukin-4 receptor alpha subunit (IL-4Rα) can reverse inflammatory dysregulation in models and prevent stress-induced social avoidance behaviors, as a recent study published in Molecular Psychiatry in February 2026 has shown.
MDD is often resistant to standard antidepressant treatments and is associated with significant morbidity and mortality. Emerging evidence suggests that a subset of MDD patients exhibit dysregulated immune responses, but clinical applications targeting these pathways remain largely unexplored. In contrast, targeted immunomodulatory therapies have revolutionized treatment for skin conditions such as AD and psoriasis.
Recognizing this gap, Helen He and colleagues designed a multi-stage back-translational study to investigate whether insights from dermatology could guide potential therapeutic strategies for MDD.
For this purpose, the multi-stage back-translational study compared blood proteomic profiles across MDD, AD, and psoriasis cohorts against healthy controls (HCs), followed by computational drug repurposing and mouse models of chronic social defeat stress (CSDS) to validate the behavioral effects of inhibiting the IL-4Rα subunit.
Key Clinical Findings of the Study Include:
- Shared Immune Profiles: The study reveals that the patients with MDD exhibit a blood proteomic signature characterized by Th2 skewing and neurovascular protein dysregulation that significantly mirrors the systemic profile of AD compared to HCs.
- Targeted Reversal: Computational drug repurposing identifies dupilumab, a biologic targeting the IL-4Rα, as a significant agent for reversing the specific inflammatory protein dysregulation associated with the Th2 axis in MDD patients.
- Stress-Response Modulation: Experimental pharmacological inhibition of the IL-4Rα pathway effectively prevents the development of social avoidance behavior in mouse models of CSDS.
- Novel Therapeutic Axis: The identification of a shared Th2 signaling signature between psychiatric and inflammatory skin conditions establishes this pathway as a viable, disease-modifying target for immunomodulatory treatment in a subset of individuals with MDD.
The authors conclude that the Th2 axis and IL-4Rα represent promising targets for developing future therapies. Furthermore, the study demonstrates that back-translational drug repurposing—leveraging insights from dermatology and computational analyses—may provide a novel approach to identifying immunomodulatory medications for psychiatric disorders.
Reference
He, H., Cathomas, F., Parise, L. F., David, E., Rizk, M., Hawkins, K., Karpman, E., Russo, S. J., Guttman, E., & Murrough, J. W. (2026). Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases. Molecular Psychiatry.
